Detailed Mechanism Funding and Narrative

Years of mechanism: 2016 2017 2018 2019 2020

Details for Mechanism ID: 18266
Country/Region: Haiti
Year: 2017
Main Partner: GHESKIO
Main Partner Program: NA
Organizational Type: NGO
Funding Agency: HHS/CDC
Total Funding: $3,000,000 Additional Pipeline Funding: N/A

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $134,120
Care: Orphans and Vulnerable Children (HKID) $569,797
Care: TB/HIV (HVTB) $86,400
Care: Pediatric Care and Support (PDCS) $15,763
Laboratory Infrastructure (HLAB) $100,000
Strategic Information (HVSI) $60,000
Sexual Prevention: Abstinence/Be Faithful (HVAB) $42,500
Testing: HIV Testing and Counseling (HVCT) $441,723
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $86,591
Treatment: Adult Treatment (HTXS) $1,353,613
Treatment: Pediatric Treatment (PDTX) $109,493
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
GEND_GBV By PEP service provision (related to sexual violence services provided) 2018 289
GEND_GBV By type of service: Physical and/or Emotional Violence (Other Post-GBV Care) 2018 33
GEND_GBV By type of service: Sexual Violence (Post-Rape Care) 2018 289
GEND_GBV Number of people receiving post-GBV care 2018 322
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2018 84,162
HTS_TST Service Delivery Point Agg Age (Facility) Index: 15+, Female, Negative 2018 2,347
HTS_TST Service Delivery Point Agg Age (Facility) Index: 15+, Male, Negative 2018 1,565
HTS_TST Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Female, Negative 2018 8,045
HTS_TST Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Male, Negative 2018 5,364
HTS_TST Service Delivery Point by Agg Age (Facility) TB: 15+, Female, Negative 2018 441
HTS_TST Service Delivery Point by Agg Age (Facility) TB: 15+, Male, Negative 2018 293
HTS_TST Service Delivery Point by Agg Age (Facility) VCT: <15, Female, Negative 2018 15,598
HTS_TST Service Delivery Point by Agg Age (Facility) VCT: <15, Male, Negative 2018 10,399
HTS_TST Service Delivery Point by Agg Age (Facility) VCT: 15+, Female, Negative 2018 9,361
HTS_TST Service Delivery Point by Agg Age (Facility) VCT: 15+, Male, Negative 2018 6,241
HTS_TST Service Delivery Point by Agg Age(Community) Mobile Testing: 15+, Female, Negative 2018 54
HTS_TST Service Delivery Point by Agg Age(Community) Mobile Testing: 15+, Male, Negative 2018 36
HTS_TST Sum of Test Result disaggregates 2018 1,762
HTS_TST_POS By Test Result: Positive 2018 1,762
HTS_TST_POS Service Delivery Point Agg Age (Facility) Index: 15+, Female, Positive 2018 166
HTS_TST_POS Service Delivery Point Agg Age (Facility) Index: 15+, Male, Positive 2018 111
HTS_TST_POS Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Female, Positive 2018 150
HTS_TST_POS Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Male, Positive 2018 100
HTS_TST_POS Service Delivery Point by Agg Age (Facility) TB: 15+, Female, Positive 2018 55
HTS_TST_POS Service Delivery Point by Agg Age (Facility) TB: 15+, Male, Positive 2018 37
HTS_TST_POS Service Delivery Point by Agg Age (Facility) VCT: <15, Female, Positive 2018 157
HTS_TST_POS Service Delivery Point by Agg Age (Facility) VCT: <15, Male, Positive 2018 105
HTS_TST_POS Service Delivery Point by Agg Age (Facility) VCT: 15+, Female, Positive 2018 450
HTS_TST_POS Service Delivery Point by Agg Age (Facility) VCT: 15+, Male, Positive 2018 300
HTS_TST_POS Service Delivery Point by Agg Age(Community) Mobile Testing: 15+, Female, Positive 2018 1
HTS_TST_POS Service Delivery Point by Agg Age(Community) Mobile Testing: 15+, Male, Positive 2018 1
OVC_SERV Age/Sex: <1 2018 240
OVC_SERV Age/Sex: 1-9 2018 960
OVC_SERV Age/Sex: 10-14 Female 2018 792
OVC_SERV Age/Sex: 10-14 Male 2018 528
OVC_SERV Age/Sex: 15-17 Female 2018 576
OVC_SERV Age/Sex: 15-17 Male 2018 384
OVC_SERV By: Age/sex: 18-24 Female 2018 432
OVC_SERV By: Age/sex: 25+ Female 2018 1,080
OVC_SERV By: Age/sex: Male 18-24 2018 288
OVC_SERV By: Age/sex: Male 25+ 2018 720
OVC_SERV Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS 2018 6,000
OVC_SERV Program Completion: Active 2018 4,092
OVC_SERV Program Completion: Exited without graduation 2018 270
OVC_SERV Program Completion: Graduation 2018 108
OVC_SERV Program Completion: Transferred 2018 1,530
OVC_SERV Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 18-24 2018 22
OVC_SERV Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 25+ 2018 486
OVC_SERV Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 18-24 2018 14
OVC_SERV Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 25+ 2018 324
OVC_SERV Required only for DREAMS countries - By service, age and sex: Education Support Female 10-14 2018 277
OVC_SERV Required only for DREAMS countries - By service, age and sex: Education Support Female 15-17 2018 86
OVC_SERV Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 25+ 2018 334
OVC_SERV Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 25+ 2018 144
OVC_SERV Required only for DREAMS countries - By service, age and sex: Social Protection Female 10-14 2018 396
OVC_SERV Required only for DREAMS countries - By service, age and sex: Social Protection Female 15-17 2018 230
OVC_SERV Required only for DREAMS countries - By service, age and sex: Social Protection Female 18-24 2018 22
OVC_SERV Sum of Age/Sex disaggregates 2018 2,280
PMTCT_ART Already on ART at beginning of current pregnancy 2018 45
PMTCT_ART New on ART 2018 64
PMTCT_ART Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy 2018 109
PMTCT_ART Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2018 6,244
PMTCT_EID Number of infants who had a virologic HIV test within 12 months of birth during the reporting period 2018 109
PMTCT_EID Number of infants with a negative virological test result between 2 and 12 months of birth 2018 48
PMTCT_EID Number of infants with a negative virological test result within 2 months of birth 2018 58
PMTCT_EID Number of infants with a positive virological test result between 2 and 12 months of birth 2018 2
PMTCT_EID Number of infants with a positive virological test result within 2 months of birth 2018 1
PMTCT_STAT By Age (Numerator): Unknown Age 2018 114
PMTCT_STAT By Number of known positives: Unknown Age 2018 51
PMTCT_STAT By Number of new negative: Unknown Age 2018 6,129
PMTCT_STAT By Number of new positives: Unknown Age 2018 64
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2018 6,244
PMTCT_STAT_den By Age (Denominator): Unknown Age 2018 13,217
PP_PREV Age/sex: 10-14 Female 2018 357
PP_PREV Age/sex: 15-19 Female 2018 259
PP_PREV Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period 2018 616
PP_PREV Sum of Age/Sex disaggregates 2018 616
TB_ART Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2018 8
TB_ART Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2018 131
TB_ART Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2018 5
TB_ART Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2018 87
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period 2018 231
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period 2018 231
TB_ART_den Aggregated Age/Sex: Female <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) 2018 8
TB_ART_den Aggregated Age/Sex: Female 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) 2018 131
TB_ART_den Aggregated Age/Sex: Male <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) 2018 5
TB_ART_den Aggregated Age/Sex: Male 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) 2018 87
TB_PREV By Age/Sex (Numerator): <15, Female 2018 77
TB_PREV By Age/Sex (Numerator): <15, Male 2018 52
TB_PREV By Age/Sex (Numerator): 15+, Female 2018 1,546
TB_PREV By Age/Sex (Numerator): 15+, Male 2018 901
TB_PREV The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period 2018 2,659
TB_PREV The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period) 2018 2,956
TB_PREV_den By Age/Sex (Denominator): <15, Female 2018 86
TB_PREV_den By Age/Sex (Denominator): <15, Male 2018 57
TB_PREV_den By Age/Sex (Denominator): 15+, Female 2018 1,718
TB_PREV_den By Age/Sex (Denominator): 15+, Male 2018 1,003
TB_STAT Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2018 56
TB_STAT Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2018 941
TB_STAT Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2018 37
TB_STAT Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2018 627
TB_STAT Number of registered new and relapsed TB cases with documented HIV status, during the reporting period 2018 1,661
TB_STAT Total number of registered new and relapsed TB cases, during the reporting period 2018 1,910
TB_STAT_den Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2018 64
TB_STAT_den Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2018 1,083
TB_STAT_den Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2018 43
TB_STAT_den Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2018 720
TX_CURR Aggregated Age/Sex: <15 Female 2018 504
TX_CURR Aggregated Age/Sex: <15 Male 2018 336
TX_CURR Aggregated Age/Sex: 15+ Female 2018 8,482
TX_CURR Aggregated Age/Sex: 15+ Male 2018 5,655
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2018 14,977
TX_CURR Sum of Aggregated Age/Sex <15 2018 840
TX_CURR Sum of Aggregated Age/Sex 15+ 2018 14,137
TX_CURR Sum of Aggregated Age/Sex disaggregates 2018 14,977
TX_NEW Aggregated Grouping by Age/Sex: <15 Female 2018 118
TX_NEW Aggregated Grouping by Age/Sex: <15 Male 2018 118
TX_NEW Aggregated Grouping by Age/Sex: 15+ Female 2018 1,697
TX_NEW Aggregated Grouping by Age/Sex: 15+ Male 2018 1,229
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2018 3,162
TX_NEW Pregnancy status 2018 64
TX_NEW Sum of Aggregated Age/Sex disaggregates 2018 3,162
TX_PVLS Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months 2018 14,976
TX_PVLS Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months 2018 11,232
TX_PVLS Numerator: Aggregate Age/Sex by Indication: <15 Female Routine 2018 303
TX_PVLS Numerator: Aggregate Age/Sex by Indication: <15 Female Targeted 2018 34
TX_PVLS Numerator: Aggregate Age/Sex by Indication: <15 Male Routine 2018 202
TX_PVLS Numerator: Aggregate Age/Sex by Indication: <15 Male Targeted 2018 23
TX_PVLS Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine 2018 6,065
TX_PVLS Numerator: Aggregate Age/Sex by Indication: 15+ Female Targeted 2018 674
TX_PVLS Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine 2018 3,538
TX_PVLS Numerator: Aggregate Age/Sex by Indication: 15+ Male Targeted 2018 393
TX_PVLS Numerator: Indication: Routine 2018 10,109
TX_PVLS Numerator: Indication: Targeted 2018 1,123
TX_PVLS Numerator: Preg/BF by Indication: Pregnant Routine 2018 386
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Female Routine 2018 404
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted 2018 45
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Male Routine 2018 269
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted 2018 30
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine 2018 8,087
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted 2018 899
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine 2018 4,717
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted 2018 524
TX_PVLS_den Denominator: Indication: Routine 2018 13,478
TX_PVLS_den Denominator: Indication: Targeted 2018 1,497
TX_PVLS_den Denominator: Preg/BF by Indication: Pregnant Routine 2018 386
TX_RET Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2018 63
TX_RET Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2018 42
TX_RET Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2018 1,226
TX_RET Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2018 817
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2018 2,148
TX_RET Numerator by Status: Pregnant 2018 181
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2018 2,864
TX_RET_den Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2018 86
TX_RET_den Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2018 57
TX_RET_den Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2018 1,718
TX_RET_den Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2018 1,003
TX_RET_den Denominator by Status: Pregnant 2018 181
TX_TB Number of ART patients who were screened for TB at least once during the reporting period 2018 13,345
TX_TB Number of ART patients who were started on TB treatment during the reporting period 2018 27
TX_TB Numerator: By Aggregated Age/Sex: <15, Male 2018 1
TX_TB Numerator: By Aggregated Age/Sex: 15+, Female 2018 16
TX_TB Numerator: By Aggregated Age/Sex: 15+, Male 2018 10
TX_TB_den Denominator: By Aggregated Age/Sex: <15, Female 2018 401
TX_TB_den Denominator: By Aggregated Age/Sex: <15, Male 2018 267
TX_TB_den Denominator: By Aggregated Age/Sex:15+, Female 2018 8,007
TX_TB_den Denominator: By Aggregated Age/Sex:15+, Male 2018 4,670
TX_TB_den Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay 2018 1,334
TX_TB_den Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only 2018 1,334
TX_TB_den Denominator: By Screen Result: Negative 2018 10,677
TX_TB_den Denominator: By Screen Result: Positive 2018 2,668
TX_TB_den Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease 2018 2,668
Cross Cutting Budget Categories and Known Amounts Total: $1,035,000
Key Populations: Sex Workers $35,000
Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Gender: Gender Based Violence (GBV) $150,000
GBV Prevention
Food and Nutrition: Commodities $50,000
Human Resources for Health $800,000